论文部分内容阅读
目的:评价CYP1A2基因单核苷酸多态性(SNPs)与前列腺癌分期分级的相关性。方法:对253例良性前列腺增生(BPH)患者与206例去势前列腺癌患者CYP1A2基因中rs2069514-3859(A>G)位点及rs2069525-1707(C>T)位点进行基因测序,并对各基因表型与前列腺癌的分期分级相关性进行统计学分析。结果:BPH及去势前列腺癌患者的两种CYP1A2单核苷酸多态性的发生率无明显差异(P>0.05),其基因多态性与前列腺癌的病理分期均无相关性(P>0.05);但rs2069525-1707(C>T)中含C等位基因型的前列腺癌Gleason评分多在7分以下(P=0.030,OR=4.658,95%CI:1.222～17.754)。结论:CYP1A2基因的SNPs与前列腺癌的病理分级之间可能有一定的相关性,但其发生机制及临床意义有待进一步证实及研究。
OBJECTIVE: To evaluate the association of CYP1A2 single nucleotide polymorphisms (SNPs) with staging of prostate cancer. Methods: The rs2069514-3859 (A> G) and rs2069525-1707 (C> T) sites in CYP1A2 gene were genotyped in 253 patients with benign prostatic hyperplasia (BPH) and 206 patients with prostate cancer. Statistical analysis was made on the correlation between phenotypes and staging grade of prostate cancer. Results: There was no significant difference in the incidence of the two CYP1A2 SNPs between BPH and ovariectomized prostate cancer patients (P> 0.05). There was no correlation between the polymorphism and the pathological stage of prostate cancer (P> 0.05). However, Gleason score of prostate cancer with C allele in rs2069525-1707 (C> T) was more than 7 points (P = 0.030, OR = 4.658, 95% CI: 1.222-17.754). Conclusion: There may be some correlation between the SNPs of CYP1A2 gene and the pathological grade of prostate cancer, but its mechanism and clinical significance need to be further confirmed and studied.